Stockreport

LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs

Rafael Holdings, Inc. Class B  (RFL) 
NASDAQ:AMEX Investor Relations: morningstar.com/funds/xnas/rytnx/quote.html
PDF JERUSALEM, Jan. 23, 2020 (GLOBE NEWSWIRE) -- LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and [Read more]